<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2025-6068</article-id><article-id custom-type="edn" pub-id-type="custom">CARTWA</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-6068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАРУШЕНИЯ ЛИПИДНОГО ОБМЕНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LIPID METABOLISM DISORDERS</subject></subj-group></article-categories><title-group><article-title>Анализ факторов риска аортального стеноза у пациентов с семейной гиперхолестеринемией</article-title><trans-title-group xml:lang="en"><trans-title>Analysis of risk factors for aortic stenosis in patients with familial hypercholesterolemia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6654-1382</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корнева</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Korneva</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Корнева Виктория Алексеевна — д.м.н., доцент, зав. кафедрой факультетской терапии, фтизиатрии, инфекционных болезней и эпидемиологии медицинского института.</p><p>Петрозаводск</p></bio><bio xml:lang="en"><p>Petrozavodsk</p></bio><email xlink:type="simple">vikkorneva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2231-4695</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузнецова</surname><given-names>Т. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuznetsova</surname><given-names>T. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузнецова Татьяна Юрьевна — к.м.н., доцент кафедры факультетской терапии, фтизиатрии, инфекционных болезней и эпидемиологии медицинского института.</p><p>Петрозаводск</p></bio><bio xml:lang="en"><p>Petrozavodsk</p></bio><email xlink:type="simple">eme@karelia.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Петрозаводский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Petrozavodsk State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Петрозаводский государственный университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Petrozavodsk State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>09</month><year>2024</year></pub-date><volume>30</volume><issue>1</issue><fpage>6068</fpage><lpage>6068</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Корнева В.А., Кузнецова Т.Ю., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Корнева В.А., Кузнецова Т.Ю.</copyright-holder><copyright-holder xml:lang="en">Korneva V.A., Kuznetsova T.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/6068">https://russjcardiol.elpub.ru/jour/article/view/6068</self-uri><abstract><sec><title>Цель</title><p>Цель. Проанализировать факторы, влияющие на развитие аортального стеноза (АС) у пациентов с гетерозиготной семейной гиперхолестеринемией (СГХС).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Обследовано 114 пациента с гетерозиготной СГХС (средний возраст 54,3±2,7 лет, мужчин 85 (69,1%)), из них у 10 (8,8%) человек выявлен АС. СГХС диагностировалась по критериям Dutch Lipid Clinic Network. Проанализированы показатели липидного спектра, уровень липопротеида(а) (Лп(а)), возраст, отягощенная наследственность по сердечно-сосудистой патологии, курение, артериальная гипертензия (АГ), гипергликемия; учитывался факт наличия в анамнезе ишемической болезни сердца (ИБС), инфаркта миокарда (ИМ) и ишемического инсульта. Кумулятивные уровни липопротеидов низкой плотности (ЛНП) (КЛНП) и холестерина (ХС) неЛВП рассчитывались как суммарный показатель ХС ЛНП за годы жизни пациента с учетом достигнутых показателей на фоне гиполипидемической терапии.</p></sec><sec><title>Результаты</title><p>Результаты. На развитие АС влияли возраст (отношение шансов (ОШ) 1,1 [1,02; 1,15], р=0,009); АГ (ОШ 8,15 [1,50; 44,08], р=0,017), показатели липидного спектра: общего ХС (ОШ 2,09 [1,38; 3,10], р=0,0006; ХС ЛНП (ОШ 2,8 [1,59; 4,79], р=0,0004), ХС неЛВП (ОШ 1,012 [1,005; 1,019], р=0,003), триглицеридов (ОШ 1,97 [1,33; 2,87], р=0,0007). Кумулятивные показатели также влияли на риск развития АС: КЛНП, накопленный за годы жизни (ОШ 2,13 [1,31; 3,54], р=0,003), кумулятивный уровень ХС неЛВП, накопленный за жизнь (ОШ 1,56 [1,01; 2,18], р=0,013), уровень Лп(а) (риск развития АС увеличивается в 10,6 раз при повышении Лп(а) на 1 единицу измерения (1 г/л)) (ОШАС=10,5 [5,0; 21,9], p=0,0017).</p><p>Наличие ИБС и ИМ при СГХС повышает риск развития АС (для ИБС ОШ 8,62 [1,07; 69,113], р=0,044; для ИМ ОШ 3,93 [1,08; 14,36], р=0,034). Сочетание ИМ и нарушения мозгового кровообращения в 4,94 повышает риск развития АС (ОШ 4,94 [1,23; 19,62], р=0,021). Наличие сухожильных ксантом значимо влияет на развитие АС (ОШ 50,2 [6,03; 413,00], р&lt;0,001).</p></sec><sec><title>Заключение</title><p>Заключение. Выявленный в молодом возрасте АС может быть проявлением СГХС. На развитие АС при СГХС влияют возраст и АГ, и комплекс липидных факторов: уровни общего ХС, уровни ЛНП, триглицеридов, а также уровни Лп(а) и кумулятивные показатели.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To analyze factors influencing the development of aortic stenosis (AS) in patients with heterozygous familial hypercholesterolemia (heFH).</p></sec><sec><title>Material and methods</title><p>Material and methods. A total of 114 patients with heFH were examined (mean age 54,3±2,7 years, 85 men (69,1%)), of whom 10 (8,8%) had AS. FH was diagnosed according to the Dutch Lipid Clinic Network criteria. Lipid profile parameters, lipoprotein(a) (Lp(a)) level, age, family history of cardiovascular disease, smoking, hypertension (AH), hyperglycemia were analyzed. The history of coronary artery disease (CAD), myocardial infarction (MI), and ischemic stroke was taken into account. Cumulative levels of low-density lipoprotein (LDL) and non-HDL cholesterol were calculated as the total LDL-C over the patient's life, taking into account the levels achieved during lipid-lowering therapy.</p></sec><sec><title>Results</title><p>Results. AS development was influenced by age (odds ratio (OR) 1,1 [1,02; 1,15], p=0,009), HTN (OR 8,15 [1,50; 44,08], p=0,017), lipid profile parameters: total cholesterol (OR 2,09 [1,38; 3,10], p=0,0006; LDL-C (OR 2,8 [1,59; 4,79], p=0,0004), non-HDL-C (OR 1,012 [1,005; 1,019], p=0,003), triglycerides (OR 1,97 [1,33; 2,87], p=0,0007). Cumulative indicators also influenced the risk of AS: cumulative LDL accumulated over the years of life (OR 2,13 [1,31; 3,54], p=0,003), cumulative non-HDL-C level accumulated over life (OR 1,56 [1,01; 2,18], p=0,013), Lp(a) level (AS risk increases by 10,6 times with an increase in Lp(a) by 1 unit of measurement (1 g/l) (OR 10,5 [5,0; 21,9], p=0,0017). The presence of CAD and MI in FH increases the risk of AS (for CAD, OR 8,62 [1,07; 69,113], p=0,044; for MI, OR 3,93 [1,08; 14,36], p=0,034). The combination of MI and cerebrovascular accident increases the risk of AS by 4,94 (OR 4,94 [1,23; 19,62], p=0,021). Tendon xanthomas significantly affects the AS (OR 50,2 [6,03; 413,00], p&lt;0,001).</p></sec><sec><title>Conclusion</title><p>Conclusion. AS detected at a young age can be a manifestation of FH. The development of AS in FH is influenced by age and HTN, and following lipid factors: total cholesterol, LDL, triglycerides, as well as Lp(a) levels and cumulative indicators.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>семейная гиперхолестеринемия</kwd><kwd>аортальный стеноз</kwd><kwd>факторы риска</kwd><kwd>холестерин липопротеидов низкой плотности</kwd><kwd>липопротеин(а)</kwd></kwd-group><kwd-group xml:lang="en"><kwd>familial hypercholesterolemia</kwd><kwd>aortic stenosis</kwd><kwd>risk factors</kwd><kwd>low-density lipoprotein cholesterol</kwd><kwd>lipoprotein(a)</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60(19):1854-63. doi:10.1016/j.jacc.2012.02.093.</mixed-citation><mixed-citation xml:lang="en">Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60(19):1854-63. doi:10.1016/j.jacc.2012.02.093.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mata P, Alonso R, Pérez de Isla L, Badimón L. Dyslipidemia and aortic valve disease. Curr Opin Lipidol. 2021;6:349-54. doi:10.1097/MOL.0000000000000794.</mixed-citation><mixed-citation xml:lang="en">Mata P, Alonso R, Pérez de Isla L, Badimón L. Dyslipidemia and aortic valve disease. Curr Opin Lipidol. 2021;6:349-54. doi:10.1097/MOL.0000000000000794.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pérez de Isla L, Arroyo-Olivares R, Alonso R, et al. SAFEHEART researchers. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. Rev Esp Cardiol (Engl Ed). 2020;10: 828-34. doi:10.1016/j.rec.2019.10.028.</mixed-citation><mixed-citation xml:lang="en">Pérez de Isla L, Arroyo-Olivares R, Alonso R, et al. SAFEHEART researchers. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. Rev Esp Cardiol (Engl Ed). 2020;10: 828-34. doi:10.1016/j.rec.2019.10.028.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ferreira-Gonzalez I, Pinar-Sopena J, Ribera A, et al. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area. Eur J Prev Cardiol. 2013;20:1022-30. doi:10.1177/2047487312451238.</mixed-citation><mixed-citation xml:lang="en">Ferreira-Gonzalez I, Pinar-Sopena J, Ribera A, et al. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area. Eur J Prev Cardiol. 2013;20:1022-30. doi:10.1177/2047487312451238.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mundal LJ, Hovland A, Igland J, et al. Association of low-density lipoprotein cholesterol with risk of aortic valve stenosis in familial hypercholesterolemia. JAMA Cardiol. 2019;4:1156-9. doi:10.1001/jamacardio.2019.3903.</mixed-citation><mixed-citation xml:lang="en">Mundal LJ, Hovland A, Igland J, et al. Association of low-density lipoprotein cholesterol with risk of aortic valve stenosis in familial hypercholesterolemia. JAMA Cardiol. 2019;4:1156-9. doi:10.1001/jamacardio.2019.3903.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Корнева В.А., Кузнецова Т.Ю., Тихова Г. П. Анализ влияния традиционных факторов риска на развитие ишемической болезни сердца. Российский кардиологический журнал. 2017;(5):104-10. doi:10.15829/1560-4071-2017-5-104-110.</mixed-citation><mixed-citation xml:lang="en">Korneva VА, Kuznetsova ТYu, Tikhova GP. Analysis of the traditional risk factors influence on development of ischemic heart disease in familial hypercholesterolemia. Russian Journal of Cardiology. 2017;(5):104-10. (In Russ.) doi:10.15829/1560-4071-2017-5-104-110.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Корнева В.А., Кузнецова Т.Ю., Тихова Г.П. Значение определения липопротеида(а) как дополнительного маркера сердечно-сосудистого риска у пациентов с семейной гиперхолестеринемией. Российский кардиологический журнал. 2016;(6):45-9. doi:10.15829/1560-4071-2016-6-45-49.</mixed-citation><mixed-citation xml:lang="en">Korneva VA, Kuznetsova TYu, Tikhova GP. Lipoprotein (a) meaning as an additional marker of cardiovascular risk in patients with familial hypercholesterolemia. Russian Journal of Cardiology. 2016;(6):45-9. (In Russ.) doi:10.15829/1560-4071-2016-6-45-49.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pérez De Isla L, Watts GF, Alonso R, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J. 2021;42:2201-11. doi:10.1093/eurheartj/ehaa1066.</mixed-citation><mixed-citation xml:lang="en">Pérez De Isla L, Watts GF, Alonso R, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J. 2021;42:2201-11. doi:10.1093/eurheartj/ehaa1066.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Smith JG, Luk K, Schulz C-A, et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312:1764-71. doi:10.1001/jama.2014.13959.</mixed-citation><mixed-citation xml:lang="en">Smith JG, Luk K, Schulz C-A, et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312:1764-71. doi:10.1001/jama.2014.13959.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kronenberg F.Aortic valve stenosis: the long and winding road. Eur Heart J. 2021;42: 2212-4. doi:10.1093/eurheartj/ehaa1069.</mixed-citation><mixed-citation xml:lang="en">Kronenberg F.Aortic valve stenosis: the long and winding road. Eur Heart J. 2021;42: 2212-4. doi:10.1093/eurheartj/ehaa1069.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nazarzadeh M, Pinho-Gomes AC, Bidel Z, et al. Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study. Eur Heart J. 2020;41:3913-20. doi:10.1093/eurheartj/ehaa070.</mixed-citation><mixed-citation xml:lang="en">Nazarzadeh M, Pinho-Gomes AC, Bidel Z, et al. Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study. Eur Heart J. 2020;41:3913-20. doi:10.1093/eurheartj/ehaa070.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Schnitzler JG, Ali L, Groenen AG, et al. Lipoprotein(A) as orchestrator of calcific aortic valve stenosis. Biomolecules. 2019;9:760. doi:10.3390/biom9120760.</mixed-citation><mixed-citation xml:lang="en">Schnitzler JG, Ali L, Groenen AG, et al. Lipoprotein(A) as orchestrator of calcific aortic valve stenosis. Biomolecules. 2019;9:760. doi:10.3390/biom9120760.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66:1236-46.</mixed-citation><mixed-citation xml:lang="en">Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66:1236-46.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kaiser Y, Singh SS, Zheng KH, et al. Lipoprotein(a) is robustly associated with aortic valve calcium. Heart. 2021;107:1422-8. doi:10.1136/heartjnl-2021-319044.</mixed-citation><mixed-citation xml:lang="en">Kaiser Y, Singh SS, Zheng KH, et al. Lipoprotein(a) is robustly associated with aortic valve calcium. Heart. 2021;107:1422-8. doi:10.1136/heartjnl-2021-319044.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73:2150-62.</mixed-citation><mixed-citation xml:lang="en">Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73:2150-62.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
